Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2.
The mechanisms involved in spironolactone (SL, 200 micromol/kg body weight, 3 days i.p.)-induced choleresis were explored in vivo by evaluating bile salt export pump (Bsep)-, multidrug resistance-associated protein 2 (Mrp2)-, and anion exchanger 2 (AE2)-mediated secretory processes in rat liver. Hepatic bile salt metabolism was also analyzed. Total bile flow was significantly increased by SL, primarily due to an increase in bile salt-independent bile flow, whereas bile salt secretion was decreased. SL did not produce any choleresis in TR(-) rats. SL decreased the de novo bile salt synthesis rate in concordance with impaired microsomal cholesterol 7 alpha-hydroxylase activity, thus leading to a decrease in endogenous bile salt pool size. In contrast, the maximum secretory rate of tauroursodeoxycholate as well as expression of Bsep protein detected by Western blotting were not affected. Thus, decreased bile salt availability for canalicular transport rather than transport capability itself likely explains reduced biliary secretion of bile salts. Biliary secretion of glutathione, an endogenous substrate of Mrp2, and HCO(3)(-), the AE2 substrate, were increased by SL, as a main factor explaining enhanced bile salt-independent bile flow. Western blot studies revealed increased expression of Mrp2 in response to SL whereas AE2 content remained unchanged. Enhanced activity and expression of Mrp2 was confirmed by analyzing the excretion rate of dinitrophenyl S-glutathione, an exogenous substrate of Mrp2, in isolated hepatocytes and by immunofluorescence microscopy, respectively. We conclude that SL increased bile flow mainly by increasing the biliary secretion of glutathione species and HCO(3)(-); increased expression of Mrp2 is also involved.
Ruiz
María L
ML
Instituto de Fisiología Experimental (CONICET), Facultad de Ciencias, Bioquímicas y Farmacéutica (UNR), Suipacha 570, Rosario 2000, Argentina.
Villanueva
Silvina S M
SS
Luquita
Marcelo G
MG
Sánchez-Pozzi
Enrique J
EJ
Crocenzi
Fernando A
FA
Pellegrino
José M
JM
Ochoa
Justina E
JE
Vore
Mary
M
Mottino
Aldo D
AD
Catania
Viviana A
VA
D000074020:ATP Binding Cassette Transporter, Subfamily B, Member 11; D018528:ATP-Binding Cassette Transporters / Q000235:genetics / Q000502:physiology; D000818:Animals; D027321:Anion Transport Proteins / Q000235:genetics / Q000502:physiology; D017920:Antiporters / Q000235:genetics / Q000502:physiology; D001646:Bile / Q000187:drug effects* / Q000378:metabolism; D001692:Biological Transport; D022781:Hepatocytes / Q000378:metabolism; D008297:Male; D026901:Membrane Transport Proteins / Q000235:genetics / Q000502:physiology*; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D064606:SLC4A Proteins; D013148:Spironolactone / Q000494:pharmacology*
D000074020:ATP Binding Cassette Transporter, Subfamily B, Member 11; D018528:ATP-Binding Cassette Transporters; D027321:Anion Transport Proteins; D017920:Antiporters; D026901:Membrane Transport Proteins; D000089762:Multidrug Resistance-Associated Protein 2; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D064606:SLC4A Proteins; D013148:Spironolactone; C490548:Abcb11 protein, rat